These results demonstrate how the dual inhibition of Akt and mTOR could prove to be a promising therapeutic strategy, since hyperactivation of the PI3K/Akt/mTOR pathway represents a hallmark of ALL contributing to poor clinical outcomes [103]. Here, PIK3CD is linked to acute lymphoblastic leukemia.